# Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo

> **NCT02505542** · PHASE3 · COMPLETED · sponsor: **UCB BIOSCIENCES GmbH** · enrollment: 736 (actual)

## Conditions studied

- Axial Spondyloarthrithis
- Ankylosing Spondylitis

## Interventions

- **BIOLOGICAL:** Certolizumab Pegol
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02505542
- **Lead sponsor:** UCB BIOSCIENCES GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2019-02
- **Final completion:** 2019-04
- **Target enrollment:** 736 (ACTUAL)
- **Last updated:** 2020-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02505542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02505542, "Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02505542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*